EUVIMEDEUVIMED entdecken
Crossref

Metformin and renal dosimetry in patients undergoing [177Lu]Lu-PSMA therapy: reduced kidney absorbed dose without impact on tumor dosimetry

Sophie Carina Siegmund, Astrid Delker, Liam Widjaja, Johannes Hornfeck, Muyu Wu, Lena M Unterrainer, Franz Josef Gildehaus, Guido Böning, Rudolf A Werner, Zachary Ells

European Journal of Nuclear Medicine and Molecular Imaging · 2026-10 · 53 (12) · 6849-6857

DOI: 10.1007/s00259-026-08030-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 26.06.2026. Verfasst von Sophie Carina Siegmund und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, LMU University Hospital, LMU Medizin, LMU Munich, Marchioninistr. 15, Munich, 81377, Germany. sophie.siegmund@med.uni…. Hauptthemen laut MEDLINE: Metformin, Kidney, Prostatic Neoplasms, Antigens, Surface. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Munich Clinician Scientist Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminKidneyProstatic NeoplasmsAntigens, SurfaceLutetiumGlutamate Carboxypeptidase IIHeterocyclic Compounds, 1-RingRadiation DosageDipeptidesHumansMaleAgedRadiometryRetrospective StudiesMiddle AgedRadiopharmaceuticalsRadioisotopesAged, 80 and overProstate-Specific Antigen

Stichwörter der Autor:innen

DosimetryKidney absorbed doseMetforminPSMA radiopharamceutical therapyTumor dose

Substanzen

MetforminAntigens, SurfaceLutetiumGlutamate Carboxypeptidase IILutetium-177FOLH1 protein, humanRadiopharmaceuticalslutetium (177Lu) vipivotide tetraxetanHeterocyclic Compounds, 1-RingRadioisotopes

Autor:innen und Institutionen

  • Department of Nuclear Medicine, LMU University Hospital, LMU Medizin, LMU Munich, Marchioninistr. 15, Munich, 81377, Germany. sophie.siegmund@med.uni-muenchen.de.
  • Department of Nuclear Medicine, LMU University Hospital, LMU Medizin, LMU Munich, Marchioninistr. 15, Munich, 81377, Germany.
  • Department of Nuclear Medicine, Klinikum Rechts Der Isar, Technical University of Munich, Munich, Germany.
  • Interdisciplinary Center of Neuroendocrine Tumors of the GastroEnteroPancreatic System (GEPNET- KUM, ENETS Certified Center of Excellence), LMU University Hospital, LMU Medizin, LMU Munich, Munich, Germany.
  • Department of Nuclear Medicine and Theranostics, Ahmanson Translational Theranostics Division, David Geffen School of Medicine at UCLA, University of California Los Angeles UCLA, Los Angeles, CA, USA.

Förderung

  • Munich Clinician Scientist Program

Zitieren

APA

Siegmund, S. C., Delker, A., Widjaja, L., Hornfeck, J., Wu, M., Unterrainer, L. M., Gildehaus, F. J., Böning, G., Werner, R. A., & Ells, Z. (2026). Metformin and renal dosimetry in patients undergoing [177Lu]Lu-PSMA therapy: reduced kidney absorbed dose without impact on tumor dosimetry. European Journal of Nuclear Medicine and Molecular Imaging, 53(12), 6849-6857. https://doi.org/10.1007/s00259-026-08030-x

Vancouver

Siegmund SC, Delker A, Widjaja L, Hornfeck J, Wu M, Unterrainer LM, et al. Metformin and renal dosimetry in patients undergoing [177Lu]Lu-PSMA therapy: reduced kidney absorbed dose without impact on tumor dosimetry. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(12):6849-6857. doi:10.1007/s00259-026-08030-x

BibTeX
@article{Siegmund2026,
  author = {Siegmund, Sophie Carina and Delker, Astrid and Widjaja, Liam and Hornfeck, Johannes and Wu, Muyu and Unterrainer, Lena M and Gildehaus, Franz Josef and Böning, Guido and Werner, Rudolf A and Ells, Zachary},
  title = {Metformin and renal dosimetry in patients undergoing [177Lu]Lu-PSMA therapy: reduced kidney absorbed dose without impact on tumor dosimetry},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  volume = {53},
  number = {12},
  pages = {6849--6857},
  doi = {10.1007/s00259-026-08030-x}
}
Kostenlos starten →